Sugi Predict

Sugi Predict / Compounds / SCHEMBL2937360

SCHEMBL2937360

SCHEMBL2937360

CC(C)(C)OC(=O)N1CC(CO)C(CO)C1

nearest known ligand 0.65

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ NR1H2 P55055 1/20 0.65
▸ PDE4B Q07343 2/20 0.47
▸ USP2 O75604 1/20 0.46
▸ SMN1; SMN2 Q16637 1/20 0.46
▸ NAMPT P43490 1/20 0.43
▸ HPGD P15428 1/20 0.42
▸ MEN1 O00255 1/20 0.42
▸ ALDH1A1 P00352 1/20 0.42
▸ MAPT P10636 1/20 0.42
▸ KMT2A Q03164 1/20 0.42
▸ RECQL P46063 1/20 0.41
▸ EPHX1 P07099 1/20 0.41
▸ DDB1 Q16531 1/20 0.40
▸ CRBN Q96SW2 1/20 0.40
▸ CHRM2 P08172 1/20 0.40
▸ CHRM1 P11229 1/20 0.40
▸ CHRM3 P20309 1/20 0.40
▸ RORC P51449 1/20 0.39
▸ EPHX2 P34913 1/20 0.39
▸ KDM4E B2RXH2 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30721755 1.00 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL1014216 1.00 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL2930155 1.00 NR1H2 (0.65) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL19123143 0.95 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL19385238 0.95 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL30835821 0.95 NR1H2 (0.59) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL17841889 0.93 NR1H2 (0.58) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL19695882 0.92 NR1H2 (0.56) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL16963312 0.92 NR1H2 (0.56) NR1H2PDE4BUSP2SMN1; SMN2NAMPT
SCHEMBL17310854 0.92 NR1H2 (0.56) NR1H2PDE4BUSP2SMN1; SMN2NAMPT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2025052278-A1 PYRROLIDINE BASED CATIONIC LIPIDS FOR LIPID NANOPARTICLE DELIVERY OF THERAPEUTICS TO HEPATIC STELLATE CELLS GENEVANT SCIENCES GMBH (CH) 2025-03-13 — — WO disclosed
EP-4472963-A1 DGK TARGETING COMPOUNDS AND USES THEREOF Arvinas Operations, Inc. (US) 2024-12-11 — — EP disclosed
CN-118946556-A DGK targeting compounds and uses thereof 阿维纳斯运营公司 2024-11-12 — — CN disclosed
CN-116829559-A Carbonyl substituted diazaspiro compounds and uses thereof 烨辉医药科技(上海)有限公司 2023-09-29 — — CN disclosed
WO-2023150186-A1 DGK TARGETING COMPOUNDS AND USES THEREOF ARVINAS OPERATIONS, INC. (US) 2023-08-10 — — WO disclosed
US-11685714-B2 Prodrugs of cytotoxic active agents having enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-06-27 — — US disclosed
US-11685714-B2 Prodrugs of cytotoxic active agents having enzymatically cleavable groups BAYER PHARMA AKTIENGESELLSCHAFT (DE) 2023-06-27 — — US disclosed
WO-2023001069-A1 MACROCYCLIC AMIDE COMPOUNDS AND APPLICATION THEREOF 南京明德新药研发有限公司 2023-01-26 — — WO disclosed
EP-3590940-B1 HEXAHYDROPYRROLO[3,4-C]PYRROLE DERIVATIVES AND RELATED COMPOUNDS AS AUTOTAXIN (ATX) INHIBITORS AND AS INHIBITORS OF THE LYSOPHOSPHATIDIC ACID (LPA) PRODUCTION FOR TREATING E.G. RENAL DISEASES HOFFMANN LA ROCHE (CH) 2021-06-09 — — EP disclosed
US-10913745-B2 Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors HOFFMANN-LA ROCHE INC. (US) 2021-02-09 — — US disclosed
EP-2567951-A1 CATIONIC LIPID Kyowa Hakko Kirin Co., Ltd. (JP) 2013-03-13 — — EP disclosed
EP-1863477-B1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2010-11-03 — — EP disclosed
US-7807709-B2 Organic compounds NOVARTIS AG (CH) 2010-10-05 — — US disclosed
EP-1836163-B1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2010-09-22 — — EP disclosed
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN BREITENSTEIN WERNER 2010-04-08 — — US disclosed
US-20080194549-A1 Organic Compounds NOVARTIS AG (CH) 2008-08-14 — — US disclosed
EP-1863477-A1 3,4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION Novartis AG (CH) 2007-12-12 — — EP disclosed
EP-1836163-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN Novartis AG (CH) 2007-09-26 — — EP disclosed
WO-2006100036-A1 3, 4-SUBSTITUTED PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF HYPERTENSION NOVARTIS AG (CH) 2006-09-28 — — WO disclosed
WO-2006066896-A2 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN NOVARTIS AG (CH) 2006-06-29 — — WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-11685714-B2 Prodrugs of cytotoxic active agents having enzymatically cleavable groups BUB1B, KIF5B, TK1 NR1H2 3002/4885PDE4B 3084/4885USP2 770/4885
US-20100087427-A1 PYRROLIDINE DERIVATIVES FOR THE TREATMENT OF A DISEASE DEPENDING ON THE ACTIVITY OF RENIN REN, ACE, PEPD NR1H2 2641/4885PDE4B 377/4885USP2 3916/4885
US-10913745-B2 Octahydro-pyrrolo[3,4-c]-pyrrole derivatives and analogs thereof as autotaxin inhibitors ENPP2, TPX2, PRAP1 NR1H2 4464/4885PDE4B 2201/4885USP2 1422/4885
US-20080194549-A1 Organic Compounds REN, ACE, OTC NR1H2 2620/4885PDE4B 1099/4885USP2 4135/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.